As previously detailed, drugs and treatments inhibiting LRRK2 to treat PD have been shown to induce pathologies in peripheral organs, particularly the kidney and lungs (Herzig et al., 2011, Hinkle et al., 2012, Tong et al., 2010). This evidence concerns the gene LRRK2 and Parkinson disease.